Current therapies for nonalcoholic fatty liver disease

Drugs of Today

Volumn 47, Issue 12, 2011, Pages 915-922

  Gossard, Andrea A ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; BETAINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

BARIATRIC SURGERY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; STEATOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANTIOXIDANTS; BARIATRIC SURGERY; EXERCISE; FATTY LIVER; HUMANS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; LIVER; WEIGHT LOSS;

EID: 84856587157     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.12.1688530     Document Type: Review

References (43)

1. Kopelman, P.G. Obesity as a medical problem. Nature 2000, 404(6778): 635-43. (Pubitemid 30205068)
2. Feldstein, A.E., Charatcharoenwitthaya, P., Treeprasertsuk, S., Benson, J.T., Enders, F.B., Angulo, P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58(11): 1538-44.
3. Day, C.P., James, O.F. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998, 27(6): 1463-6. (Pubitemid 28264666)
4. Day, C.P., James, O.F. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998, 114(4): 842-5.
5. Neuschwander-Tetri, B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52(2): 774-88.
6. Stefan, N., Kantartzis, K., Haring, H.U. Causes and metabolic consequences of fatty liver. Endocr Rev 2008, 29(7): 939-60.
7. Tamura, Y., Tanaka, Y., Sato, F. et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005, 90(6): 3191-6. (Pubitemid 41014274)
8. Angulo, P., Keach, J.C., Batts, K.P., Lindor, K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6): 1356-62.
9. Harrison, S.A., Torgerson, S., Hayashi, P., Ward, J., Schenker, S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98(11): 2485-90. (Pubitemid 37448761)
10. Kugelmas, M., Hill, D.B., Vivian, B., Marsano, L., McClain, C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38(2): 413-9. (Pubitemid 36919862)
11. Lavine, J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000, 136(6): 734-8. (Pubitemid 30415645)
12. Miller, E.R., 3rd, Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J., Guallar, E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142(1): 37-46.
13. Caldwell, S.H., Hespenheide, E.E., Redick, J.A., Iezzoni, J.C., Battle, E.H., Sheppard, B.L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96(2): 519-25.
14. Watkins, P.B., Whitcomb, R.W. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998, 338(13): 916-7.
15. Saryusz-Wolska, M., Szymanska-Garbacz, E., Jablkowski, M. et al. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. Pol Arch Med Wewn 2011, 121(3): 61-6.
16. Neuschwander-Tetri, B.A., Brunt, E.M., Wehmeier, K.R., Oliver, D., Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38(4): 1008-17. (Pubitemid 37221684)
17. Ratziu, V., Giral, P., Jacqueminet, S. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135(1): 100-10. (Pubitemid 351916703)
18. Promrat, K., Lutchman, G., Uwaifo, G.I. et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39(1): 188-96. (Pubitemid 38461481)
19. Aithal, G.P., Thomas, J.A., Kaye, P.V. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135(4): 1176-84.
20. Sanyal, A.J., Chalasani, N., Kowdley, K.V. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362(18): 1675-85.
21. Lavine, J.E., Schwimmer, J.B., Van Natta, M.L. et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305(16): 1659-68.
22. Lindor, K.D., Kowdley, K.V., Heathcote, E.J. et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39(3): 770-8. (Pubitemid 38337657)
23. Abdelmalek, M.F., Angulo, P., Jorgensen, R.A., Sylvestre, P.B., Lindor, K.D. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001, 96(9): 2711-7.
24. Abdelmalek, M.F., Sanderson, S.O., Angulo, P. et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50(6): 1818-26.
25. Wigg, A.J., Roberts-Thomson, I.C., Dymock, R.B., McCarthy, P.J., Grose, R.H., Cummins, A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of nonalcoholic steatohepatitis. Gut 2001, 48(2): 206-11. (Pubitemid 32141844)
26. Adams, L.A., Zein, C.O., Angulo, P., Lindor, K.D. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99(12): 2365-8. (Pubitemid 40039367)
27. Zein, C.O., Yerian, L.M., Gogate, P., Lopez, R., Kirwan, J., Feldstein, A.E., McCullough, A.J. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011, 54(5): 1610-9.
28. Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Holmqvist, M., Bodemar, G., Kechagias, S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007, 47(1): 135-41. (Pubitemid 46817693)
29. Nelson, A., Torres, D.M., Morgan, A.E., Fincke, C., Harrison, S.A. A pilot study using simvastatin in the treatment of non-alcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009, 43(10): 990-4.
30. Hyogo, H., Tazuma, S., Arihiro, K. et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008, 57(12): 1711-8.
31. Belfort, R., Harrison, S.A., Brown, K. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355(22): 2297-307. (Pubitemid 44837778)
32. Foster, T., Budoff, M.J., Saab, S., Ahmadi, N., Gordon, C., Guerci, A.D. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011, 106(1): 71-7.
33. Assy, N., Hussein, O., Abassi, Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007, 56(3): 443-4. (Pubitemid 46579783)
34. Harrison, S.A., Fecht, W., Brunt, E.M., Neuschwander-Tetri, B.A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009, 49(1): 80-6.
35. Mummadi, R.R., Kasturi, K.S., Chennareddygari, S., Sood, G.K. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008, 6(12): 1396-402.
36. Mathurin, P., Hollebecque, A., Arnalsteen, L. et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009, 137(2): 532-40.
37. Suzuki, A., Lindor, K., St Saver, J. et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005, 43(6): 1060-6. (Pubitemid 41627993)
38. Jurca, R., Lamonte, M.J., Church, T.S. et al. Associations of muscle strength and fitness with metabolic syndrome in men. Med Sci Sports Exerc 2004, 36(8): 1301-7. (Pubitemid 39014812)
39. Irwin, M.L., Ainsworth, B.E., Mayer-Davis, E.J., Addy, C.L., Pate, R.R., Durstine, J.L. Physical activity and the metabolic syndrome in a tri-ethnic sample of women. Obes Res 2002, 10(10): 1030-7. (Pubitemid 135688920)
40. Farrell, S.W., Cheng, Y.J., Blair, S.N. Prevalence of the metabolic syndrome across cardiorespiratory fitness levels in women. Obes Res 2004, 12(5): 824-30. (Pubitemid 41127318)
41. Lakka, T.A., Laaksonen, D.E., Lakka, H.M., Mannikko, N., Niskanen, L.K., Rauramaa, R., Salonen, J.T. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med Sci Sports Exerc 2003, 35(8): 1279-86. (Pubitemid 36936144)
42. Caldwell, S., Lazo, M. Is exercise an effective treatment for NASH? Knowns and unknowns. Ann Hepatol 2009, 8(Suppl. 1): S60-6.
43. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., Nathan, D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346(6): 393-403. (Pubitemid 34437694)